PDM
BMY icon

Penn Davis McFarland’s Bristol-Myers Squibb BMY Stock Holding History

Penn Davis McFarland’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9M Sell
240,615
-95,649
-28% -$5.49M 1.24% 23
2026
Q1 		$20.4M Sell
336,264
-1,989
-0.6% -$116K 2% 19
2025
Q4 		$18.2M Sell
338,253
-13,404
-4% -$645K 1.75% 19
2025
Q3 		$15.9M Sell
351,657
-4,953
-1% -$231K 1.64% 20
2025
Q2 		$16.5M Sell
356,610
-1,173
-0.3% -$57.6K 1.86% 19
2025
Q1 		$21.8M Sell
357,783
-46
-0% -$2.68K 2.58% 17
2024
Q4 		$20.2M Buy
357,829
+7
+0% +$391 2.2% 19
2024
Q3 		$18.5M Sell
357,822
-964
-0.3% -$45.2K 2.08% 20
2024
Q2 		$14.9M Sell
358,786
-470
-0.1% -$21K 2.3% 20
2024
Q1 		$19.5M Sell
359,256
-4,044
-1% -$206K 3.02% 20
2023
Q4 		$18.6M Sell
363,300
-7,359
-2% -$386K 3.17% 18
2023
Q3 		$21.5M Sell
370,659
-6,782
-2% -$416K 3.77% 12
2023
Q2 		$24.1M Sell
377,441
-2,110
-0.6% -$141K 4.3% 10
2023
Q1 		$26.3M Sell
379,551
-1,251
-0.3% -$88.2K 4.83% 8
2022
Q4 		$27.4M Sell
380,802
-7,525
-2% -$567K 5.37% 7
2022
Q3 		$27.6M Sell
388,327
-204
-0.1% -$14.8K 5.54% 6
2022
Q2 		$29.9M Sell
388,531
-15,943
-4% -$1.21M 5.63% 2
2022
Q1 		$29.5M Sell
404,474
-11,395
-3% -$765K 4.74% 8
2021
Q4 		$25.9M Buy
415,869
+1,812
+0.4% +$106K 4.4% 7
2021
Q3 		$24.5M Sell
414,057
-2,452
-0.6% -$161K 4.48% 7
2021
Q2 		$27.8M Buy
416,509
+8,863
+2% +$578K 4.87% 6
2021
Q1 		$25.7M Buy
407,646
+682
+0.2% +$42.4K 4.93% 5
2020
Q4 		$25.2M Buy
406,964
+8,406
+2% +$517K 5.41% 4
2020
Q3 		$24M Buy
398,558
+102
+0% +$6.14K 6.25% 4
2020
Q2 		$23.4M Sell
398,456
-1,459
-0.4% -$87.3K 6.36% 3
2020
Q1 		$22.3M Sell
399,915
-17,431
-4% -$1.07M 7.74% 2
2019
Q4 		$26.8M Buy
417,346
+201,695
+94% +$11.6M 7.94% 3
2019
Q3 		$10.9M Buy
215,651
+2,278
+1% +$107K 3.42% 12
2019
Q2 		$9.68M Buy
213,373
+46,903
+28% +$2.18M 3.27% 15
2019
Q1 		$7.94M Buy
166,470
+16,131
+11% +$804K 2.75% 16
2018
Q4 		$7.82M Buy
150,339
+15,808
+12% +$849K 3.04% 15
2018
Q3 		$8.35M Sell
134,531
-1,776
-1% -$105K 2.41% 18
2018
Q2 		$7.54M Buy
136,307
+1,597
+1% +$86.3K 2.32% 21
2018
Q1 		$8.52M Sell
134,710
-622
-0.5% -$40K 2.6% 20
2017
Q4 		$8.29M Sell
135,332
-567
-0.4% -$35.5K 2.43% 20
2017
Q3 		$8.66M Sell
135,899
-4,769
-3% -$278K 2.68% 19
2017
Q2 		$7.84M Buy
140,668
+1,110
+0.8% +$60.4K 2.33% 21
2017
Q1 		$7.59M Buy
+139,558
New +$7.65M 2.21% 21

Other funds holding BMY

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
ORIO
Old Republic International (ORI) Chicago, Illinois $2.67B AUM 26.94% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Penn Davis McFarland's BMY Position: Q2 2026 in Review

Penn Davis McFarland reduced its Bristol-Myers Squibb (BMY) stake by 28% in Q2 2026, selling an estimated $5.49M and leaving 240,615 shares worth $13.9M. The position accounts for 1.24% of the portfolio, ranked #23.

Penn Davis McFarland first reported a position in BMY in Q1 2017 and has held it in 38 quarters since. The position peaked at $29.9M in Q2 2022. 440 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Penn Davis McFarland held 240,615 shares of Bristol-Myers Squibb worth $13.9M as of Q2 2026.
  • Penn Davis McFarland sold 95,649 Bristol-Myers Squibb shares in Q2 2026, an estimated $5.49M.
  • Bristol-Myers Squibb made up 1.24% of Penn Davis McFarland's portfolio in Q2 2026, its #23 holding.
  • Penn Davis McFarland first reported a position in Bristol-Myers Squibb in Q1 2017 and has held it in 38 quarters since.
  • Penn Davis McFarland's Bristol-Myers Squibb position peaked at $29.9M in Q2 2022.
  • 440 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Penn Davis McFarland's 13F filing for Q2 2026, filed 15 Jul 2026.